Show simple item record

dc.contributor.authorStreit, Sven
dc.date.accessioned2021-07-09T02:02:54Z
dc.date.available2021-07-09T02:02:54Z
dc.date.issued2018
dc.date.submitted2021-07-08T11:30:07Z
dc.identifierONIX_20210708_9789463611268_150
dc.identifierhttps://library.oapen.org/handle/20.500.12657/49965
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/71145
dc.description.abstractWith increasing age, blood pressure rises as a consequence of arterial stiffness and it has been debated whether or not to it is beneficial to treat hypertension in old age especially in >75-year-olds when they have multimorbidity, polypharmacy or frailty. Large hypertension trials showed that lowering SBP in >60-year-olds is beneficial and lowers the risk for myocardial infarction, stroke and all-cause mortality, even in >80-year-olds. However, these trials lack generalizability and typically excluded multimorbid patients that are frail. At the same time, observational studies rose concerns about lowering SBP too much since there are several cohort studies showing a reverse association of low SBP and increased mortality and accelerated cognitive decline especially in >75-year-olds. However, current hypertension guidelines advise physicians to lower SBP to values of even <130mmHg in all patients from the age of 60 years, which fuelled the discussions about the benefits and harms of lowering SBP too much in >75-year-olds under antihypertensive treatment especially when they are frail defined as having low hand grip strength or complex health problems in multiple domains of daily living. The general aim of this thesis is to increase the scientific knowledge about the effects of treating hypertension in >75-year-olds with frailty. This thesis has three aims: 1) to measure the prevalence of polypharmacy in older patients; 2) to test for an association between low SBP and mortality, cognitive function, daily functioning, and QoL in older patients under antihypertensive treatment; and 3) to understand the role that frailty plays in GP decisions about treating hypertension in old age across countries and see if those differences can be explained by country-specific cardiovascular disease burden and life expectancy.
dc.languageEnglish
dc.rightsopen access
dc.subject.classificationbic Book Industry Communication::M Medicine::MJ Clinical & internal medicine::MJD Cardiovascular medicine
dc.subject.otherHypertension
dc.subject.otherOld Age
dc.subject.otherFraitly
dc.titlePerspectives on treating hypertension in old age
dc.title.alternativeThe burden of polypharmacy, risks of treatment and GPs’ treatment probability
dc.typebook
oapen.identifier.doi10.7892/boris.143354
oapen.relation.isPublishedBy5a707748-90f2-4697-b60c-19233c194410
oapen.relation.isFundedBy4bb461ae-a887-4564-b3a7-29e6d7e08318
oapen.relation.isFundedBy07f61e34-5b96-49f0-9860-c87dd8228f26
oapen.relation.isbn9789463611268
oapen.collectionSwiss National Science Foundation (SNF)
oapen.place.publicationRotterdam
oapen.grant.number10BP12_183815
oapen.grant.programOpen Access Books
dc.relationisFundedBy07f61e34-5b96-49f0-9860-c87dd8228f26
dc.grantprojectPerspectives on treating hypertension in old age - The burden of polypharmacy, risks of treatment and GPs’ treatment probability


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

open access
Except where otherwise noted, this item's license is described as open access